September 12th 2025
Bram Baert, global head of Regulatory Affairs at Lonza CHI, gives his perspective on the impact of the EC’s decision on the use of TiO2 in drug products.
September 9th 2025
September 8th 2025
The Usefulness of 0.45 µm–Rated Filter Membranes
April 1st 2002In this study, the authors examine the suitability of 0.45 µm–rated filters to be used as sterilizing and bioburden-reduction filters against significant populations of organisms such as B. diminuta in a wide range of differential pressures.
Developing Custom Adhesive Systems for Transdermal Drug Delivery
March 1st 2002Adhesives manufacturers can be involved in the development of transdermal drug delivery products by working with pharmaceutical companies on R&D, materials qualification, manufacturing, and other product development tasks.
Microbial Bioburden on Oral Solid Dosage Forms
February 1st 2002Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.
Filter Integrity Testing in Liquid Applications, Revisited Part II
November 2nd 2001In the concluding part of this article, the authors address diffusive-airflow imprecisions and measurements as well as automated integrity-test equipment, variations in bubble-point measurements, and the identification of a "sterilizing" filter.
From the Formulator to the Tablet Manufacturing Floor: Desiderata and Troubleshooting
October 1st 2001Tablet manufacturers often overlook critical basic concepts or established practices. The author draws from his own experiences and discusses how solid dosage manufacturers can improve production and product quality by optimizing major unit operations.
Current Status of Drug Delivery Technologies and Future Directions
February 2nd 2001Evolution of an existing drug molecule from a conventional form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety, and efficacy. These days,drug delivery companies are engaged in the development of multiple platform technologies to get competitive advantage, extend patent life, and increase market share of their products.